Loading
A phase 2 trial of cemiplimab in lung cancer, run by Weill Medical College of Cornell University, now recruiting.
Preoperative Radioimmunotherapy Versus Chemoimmunotherapy in NSCLC is a phase 2, randomised interventional study registered as NCT06623656 by Weill Medical College of Cornell University, with a registry enrolment figure of 112 participants, started 2025-02-21 and due to reach its primary completion in 2026-12. Interventions recorded: Cemiplimab; Platinum based chemotherapy; Stereotactic body radiation therapy. Conditions listed: Carcinoma, Non-Small-Cell Lung. Primary outcome: Number of participants with pathological complete response (pCR). Lung eligibility wording from the registry: "Patients with histologically or cytologically proven clinical stages IB (T2aN0), II, and III(N2) NSCLC (according to AJCC version 9) eligible for surgical resection with curative intent". Sites: United States. No results are recorded here; the registry entry is the source.
Shares Regeneron, Cemiplimab, Resectable stage I to III non-small-cell lung cancer, Lung cancer trials open today (registry snapshot) and the tag lung-deep-dive.
Shares Regeneron, Cemiplimab, Resectable stage I to III non-small-cell lung cancer, Lung cancer trials open today (registry snapshot) and the tag lung-deep-dive.
Shares Regeneron, Cemiplimab, Resectable stage I to III non-small-cell lung cancer, Lung cancer trials open today (registry snapshot) and the tag lung-deep-dive.
Shares Regeneron, Cemiplimab, Lung cancer trials open today (registry snapshot), Immune checkpoint inhibitors and the tag lung-deep-dive.
Shares Regeneron, Resectable stage I to III non-small-cell lung cancer, Lung cancer trials open today (registry snapshot) and the tag lung-deep-dive.
Shares Resectable stage I to III non-small-cell lung cancer, SBRT / SABR (stereotactic radiotherapy), Lung cancer trials open today (registry snapshot), Immune checkpoint inhibitors and the tag lung-deep-dive.
Shares Resectable stage I to III non-small-cell lung cancer, SBRT / SABR (stereotactic radiotherapy), Lung cancer trials open today (registry snapshot), Immune checkpoint inhibitors and the tag lung-deep-dive.
Shares Resectable stage I to III non-small-cell lung cancer, SBRT / SABR (stereotactic radiotherapy), Lung cancer trials open today (registry snapshot) and the tag lung-deep-dive.